YIELD10 BIOSCIENCE INC (YTEN)
US98585K8624 - Common Stock
Overall YTEN gets a fundamental rating of 1 out of 10. We evaluated YTEN against 588 industry peers in the Biotechnology industry. YTEN may be in some trouble as it scores bad on both profitability and health. YTEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
YTEN had negative earnings in the past year.
YTEN had a negative operating cash flow in the past year.
In the past 5 years YTEN always reported negative net income.
YTEN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of YTEN (-370.00%) is worse than 95.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -370% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-197.19%
ROA(5y)-147.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
YTEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
YTEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for YTEN has been increased compared to 1 year ago.
The number of shares outstanding for YTEN has been increased compared to 5 years ago.
The debt/assets ratio for YTEN is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -153.53, we must say that YTEN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -153.53, YTEN is not doing good in the industry: 98.12% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -153.53 |
ROIC/WACCN/A
WACC9.23%
2.3 Liquidity
A Current Ratio of 0.29 indicates that YTEN may have some problems paying its short term obligations.
YTEN has a worse Current ratio (0.29) than 96.93% of its industry peers.
A Quick Ratio of 0.29 indicates that YTEN may have some problems paying its short term obligations.
YTEN has a Quick ratio of 0.29. This is amonst the worse of the industry: YTEN underperforms 96.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.29 | ||
| Quick Ratio | 0.29 |
3. Growth
3.1 Past
YTEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.64%, which is quite impressive.
YTEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.67%.
YTEN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -36.03% yearly.
EPS 1Y (TTM)24.64%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q59.7%
Revenue 1Y (TTM)-86.67%
Revenue growth 3Y-57.83%
Revenue growth 5Y-36.03%
Revenue growth Q2Q-100%
3.2 Future
YTEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.08% yearly.
Based on estimates for the next years, YTEN will show a very strong growth in Revenue. The Revenue will grow by 288.42% on average per year.
EPS Next Y62.98%
EPS Next 2Y25.82%
EPS Next 3Y24.53%
EPS Next 5Y16.08%
Revenue Next Year2712.5%
Revenue Next 2Y607.11%
Revenue Next 3Y594.08%
Revenue Next 5Y288.42%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for YTEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for YTEN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
YTEN's earnings are expected to grow with 24.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.82%
EPS Next 3Y24.53%
5. Dividend
5.1 Amount
No dividends for YTEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
YIELD10 BIOSCIENCE INC
NASDAQ:YTEN (5/3/2024, 7:27:54 PM)
After market: 5.35 -0.25 (-4.46%)5.6
+5.37 (+2343.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap86.24M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -370% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.29 | ||
| Quick Ratio | 0.29 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)24.64%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y62.98%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-86.67%
Revenue growth 3Y-57.83%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y